Introduction
Over the past decade, threedimensional (3D) printing and related additive manufacturing (AM) technologies have started to rapidly displace traditional manufacturing in a wide range of industries and applications, from automotive to aerospace to medical devices. 1 -5 The capability to accurately deposit materials layerbylayer in 3D space with precision of <100 μ m has proven to be truly disruptive. The advantages of 3D print ing include the ability to (1) rapidly iterate designs at low cost, (2) easily customize designs for different applications, and (3) generate complex designs that are diffi cult or impossible to achieve with machining, injection molding, or other tradi tional manufacturing approaches.
While there have been advances in hardware systems, many of the major improvements in the quality of 3D printed parts are due to advances in the materials used. Whether metals, ceram ics, or polymers, it is critical that the materials have consistent chemical and physical properties in order to enable reliable fab rication of parts with high fi delity. This, in combination with process optimization, provides control over microstructure of the material and thus mechanical properties of the 3D printed part. While many established materials have been adapted and reformulated to work in AM processes, this often requires com promises in materials properties. Instead, it is the development of new materials specifi cally designed to take advantage of AM processes that represent the most exciting research in this area.
In 2015, the MRS Bulletin issue on "3D printing of bioma terials" provided a broad overview of the fi eld, with a major focus on the opportunities and challenges associated with 3D printing of established, US Food and Drug Administration (FDA)approved biomaterials for fabricating medical devices. 5 A primary advantage for these applications is the ability to easily customize the geometry to match patients' unique anatomical structure, based on computed tomography (CT) or magnetic resonance imaging (MRI) imaging data. This 3D information, in combination with new software tools for mod eling and simulation, enables the design of highperformance and patientspecifi c medical devices.
Over the past few years, multiple companies have brought products to market, including examples such as 3D printed skull plates composed of polyetherketoneketone or titanium, 6 surgical guides and implants for reconstruc tive surgery, 7 and orthopedic implants for vertebral fi xation and other applications. 8 In general, these devices use FDA approved materials for the same application, just using a different manufacturing technique. Thus, they can achieve US FDA clearance using a 510(k) approval process, 9 , 10 where companies demonstrate substantial equivalence in device performance and that the AM approach does not alter safety or effi cacy. There are similar medicaldevice approval pathways in other countries, such as the CE mark in the EU.
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Manufacturing has historically followed a mass production approach due to economies of scale and the engineering challenges of large-scale customization, leading to a one-sizefi ts-all paradigm. This manufacturing-centric approach has forced consumers and patients to adapt to medical devices in terms of anatomical fi t and biological performance, often signifi cantly decreasing their quality of life. In order to improve the biological interface with the human body, the materials science and bioengineering communities are rapidly adopting threedimensional (3D) printing, which promises high precision, automation, and a customized fi t. However, numerous design and engineering constraints, many posed by the fragile nature of living cells and soft gels, suggest exciting opportunities for further research in materials synthesis, characterization, and integration. Specifi cally, materials innovations in bioinks and support materials, coupled with improved 3D bioprinting processes for multiple materials, have the potential to empower the next generation of biology by enabling precision engineered tissues, organoids, and eventually whole organs.
The next major anticipated advance is 3D bioprinting of materials or cells for engineering tissues and biological systems. The primary advantage of AM for this application is control of scaffold architecture and material composition in 3D space. The use of cells and a broad range of biomaterials enables the fabrication of more complex tissues and biohybrid systems that can combine biologic and synthetic components. The basic 3D bioprinting paradigm (Figure 1) 11 seeks to re create tissue or organ structure and function by imaging the native architecture in 3D and then converting this into a 3D computeraided design (CAD) model that can then be printed with the appropriate cells or bioinks.
12 Specifically, bioinks are the materials that are deposited in 3D space by the printer and are an area of active research and development, as will be explained later in this article.
A range of imaging modalities can be used to create 3D data sets, including optical techniques such as confocal microscopy and optical coherence tomography, as well as medical imag ing methods such as MRI and CT. The latter enables in vivo imaging in live patients, providing the potential to engineer truly patientspecific tissue for disease or trauma repair. Conversion of medicalimaging data to 3D CAD models is now standard clinical practice for surgical planning, and similar techniques can be applied for bioprinting. However, the need to maintain cell viability and preserve the activity of biological molecules places severe restrictions on the range of environmental and processing conditions that can be used during fabrication. This is one of the primary reasons that new biomaterials and improved printing approaches are needed. For example, cells must be maintained between 4-37°C with minimal shear stress and sufficient oxygen during most bio fabrication strategies. Globular biological proteins can easily denature outside of their native operating ranges. This issue of MRS Bulletin highlights current 3D bioprinting approaches and both the advances and challenges that remain in bioinks, support materials, and multimaterials printing, as well as applications in tissue engineering and organsonachip.
Three-dimensional bioprinting approaches
Threedimensional bioprinting is uniquely positioned to engineer complex, biological systems and to recreate the mul tiscale structure-function hierarchy found in many tissues and organs. Unlike subtractive manufacturing, which has domi nated object fabrication for decades, 3D bioprinting provides the researcher access to every (x, y, z) Cartesian coordinate within a given volume. For example, microfabrication tech niques based on photolithography, such as soft lithography and microfluidics, have been widely used to engineer bio compatible systems with spatial resolution from ∼1 μm up to 1 mm. However, critical tradeoffs must be considered when designing a bioprinting system or workflow. There are many fabrication technologies that excel at specific length scales, such as electrospinning to generate nanofibers and microfabri cation, but very few that can span the full range of microscale to macroscale. This requires specific cell types to be positioned and interconnected precisely in 3D space, mimicking native tissue architec ture and physiology. Yet, an increase in feature resolution is always accompanied by dramatic increases in cost due to the precision hardware and software required to achieve such scales, and the time to fabricate a given volume of material thereby increases. Researchers must first consider the end goal for the desired tissue construct, then work back ward in a retrosynthetic analysis to determine the specific materials to use, the fabrication technology, and the desired resolution, in order to fabricate and validate the tissue prototype. For example, in heart muscle the macroscale beating (contraction) is produced by the coor dinated actuation of trillions of motor proteins at the molecular scale. 13 Since no readily avail able technology can deposit single molecules or structured tissues at the scale of native organs, researchers must choose the scale at which they would like to work.
There are four major types of 3D printing techniques commonly adapted for biofabrica tion (Figure 2) . 14, 15 In extrusion 3D printing, named fused deposition modeling (FDM) and trademarked by the inventor Stratasys in the Figure 1 . An overview of the general 3D bioprinting process with the goal of engineering a specific tissue or organ structure. The tissue or organ of interest is identified and can be explanted or characterized in vivo using optical, magnetic resonance imaging (MRI), or computed tomography (CT) 3D imaging techniques. The 3D imaging data are then segmented into a computer-aided design (CAD) file, with the type of material and cellular information dictated by the resolution and specificity of the imaging technique. The CAD model is then converted to a stereolithography (STL) file, and a slicer program is used to convert the STL into G-code, which is a specific instruction set that defines how the printer moves in 3D space to build the structure. The G-code is then sent to the 3D bioprinter, where bioinks and/or cells are used to print the structure. Finally, examples are shown of a 3D heart scaffold bioprinted from alginate based on 3D confocal imaging of an embryonic stage chick heart. Adapted with permission from Reference 11. © 2015 AAAS.
1980s, a computer controls the location of a syringe and its extrudate to deposit liquidlike materials that solidify in situ and thereby enable the buildup of a 3D structure. Cells can be mixed with aqueous extrudate, commonly referred to as "bioink," to make structures from this threadlike deposition. In inkjet printing, consumer twodimensional inkjet cartridges are adapted for bioprinting by exchanging ink dyes in the cartridge for biomaterials and living cells. Significant shear stresses are exerted on the fluid droplets, but biocompatible ejection rates have been identified. In selective laser sinter ing (SLS) a bed of powder is sintered or melted by a translat ing laser, and then a new layer of powder is swept atop the nascent part to enable buildup of a structured part. Due to the heat involved and the dry powders used, this technique is not directly compatible with deposition of cells until after the final part has been fabricated and submerged into aqueous solutions and seeded with cells. Finally, a stereolithography apparatus (SLA) utilizes photocurable resins and patterned light to selectively solidify material in a layerbylayer fashion. Recently, researchers have begun adapting photocurable hydrogels and biocompatible photopolymerization to build soft gels that entrap living cells during fabrication.
In this issue: Materials-focused challenges and applications in bioprinting
The articles in this issue of MRS Bulletin discuss current advances in the field of 3D bioprinting, the materialsfocused challenges that must be overcome to achieve new capabilities, and recent applications in the areas of tissue engineering and organsonchip. In their article in this issue, Rutz et al. 16 dis cuss the development of nextgeneration bioinks and how the material properties can be tuned to optimize cell viability during and after the printing pro cess. They highlight how bioink properties are altered by the presence and concentration of cells, and that this must be properly accounted for in order to achieve good print fidelity and cell viability.
In their article, O'Bryan et al. 17 focus on recent advances in the 3D bioprinting of soft cells and materials, broadly referred to as soft matter, using sacrificial materials. The authors discuss the material properties required for the sacrificial bioinks that serve as the temporary support structure that can be dissolved later to produce vascular channels, as well as for gel like sacrificial support materials within which soft matter can be printed (embedded) and then later released.
In their article, De Maria et al. 18 consider how to implement more advanced bioprinting systems that use multiple extruders to fabricate multimaterial, heterogeneous, and multicellular 3D structures. This is a critical capability as researchers seek to use 3D bioprinting to recreate the complexity of native tissues and organs.
Moving toward application, the article by Kilian et al. 19 in this issue highlights the current progress in and outstanding challenges for 3D bioprinting of volumetric tissues and organs. This requires consideration of the individual materials proper ties of the bioinks, support materials, and cells, as well as their interactions during and after printing.
Finally, the article by Huang et al. 20 in this issue discusses the application of bioprinting toward engineering 3D culture models and organonachip microfluidic systems. The authors highlight the capabilities and limitations of bioprinting compared to established microfabrication approaches, and how advances in multimaterial deposition and higher resolutions are critical for printing microphysiological tissue models.
This issue offers a materialsfocused overview of the current 3D bioprinting field and highlights how understanding the properties of cells, bioinks, and sacrificial materials, and the dynamic interactions between these components is critical for future applications in volumetric, engineered tissues, and organonachip systems.
Emerging and future trends Open-source 3D printing platforms for low-cost biomaterials development and biofabrication
The growth in 3D bioprinting research has been driven in part by the increased accessibility of the underlying AM technology platforms. A decade ago, most research groups either adapted existing industrialgrade rapid prototyping systems for bio printing applications, or built their own customdesigned 3D bioprinters from scratch. In both cases, the specialized exper tise in terms of hardware and software, in combination with Figure 2 . Biomanufacturing is typically approached using one of these methods previously developed for plastic 3D printing. Extrusion printing and inkjet printing utilize liquid-like precursors that can solidify in situ after extrusion or ejection and can also encapsulate cells. Selective laser sintering binds or melts dry powders one layer at a time. Finally, stereolithography uses photosensitive aqueous solutions that can be polymerized with patterned light and can also encapsulate cells.
14 Courtesy of J. Albritton and J. Miller.
the high cost of these systems, was a significant barrier to entry. However, this earlier work resulted in a number of clear successes that demonstrated the potential of 3D bioprinting as a biofabrication platform. [21] [22] [23] [24] [25] [26] This spurred the development of commercial 3D bioprinters to address the needs of the growing research community, nota ble examples being the Organovo NovoGen MMX Bioprinter and the Envisiontec 3DBioplotter (Figure 3a) . This has increased accessibility by providing turnkey bioprinting plat forms, but these systems are still cost prohibitive, typically >USD$100,000. A number of research groups and core facilities at major research universities have purchased these commer cial systems, but the install base is relatively small.
In the last five years, the emergence of the opensource and "maker" communities has led to the growth of lowcost 3D bioprinting platforms with widespread accessibility. This tran sition has been driven by a number of fundamental 3D print ing patents expiring, enabling established AM technologies to be integrated into a new generation of lowcost systems. The start of this process was the expiration of the patent for FDM in 1999, which described the process of layerbylayer 3D printing using a thermoplastic filament. 27 This technology was rapidly moved into the opensource community through the RepRap project 28 and Fab@Home 29 and resulted in the cost of FDMtype 3D printers dropping from >USD$10,000 to <USD$1000 in less than a few years. The RepRap platform has since served as the foundation for many lowcost 3D bioprinters, where the thermoplastic extruder (hot end) has been replaced with a syringebased extruder. Hinton et al. demonstrated that a USD$400 hobbyistgrade 3D printer could be modified into a functional 3D bioprinter 11 and released the mechanical design for the syringebased extruder (Figure 3b -c) using an opensource license through the National Institutes of Health 3D print exchange website. 30 Recently, startup companies have also emerged, such as CELLINK 31 and BioBots, 32 and started to produce much lower cost 3D bioprinters with entrylevel systems in the range of USD$10,000 (Figure 3d ). This combination of lowcost opensource and commercial 3D bioprinters has expanded the number of research laboratories using these technologies to more than 100, and growing. Threedimensional bioprinting encompasses more than just FDM and extrusionbased tech niques, and recent patents that have expired in FDM, SLA, and SLS have expanded the range of lowcost AM processes accessible to biomaterials researchers.
Kinstlinger et al. demonstrated an opensource modifica tion to a commercial laser cutter that incorporated powder handling to generate a lowcost SLS machine to work with poly(caprolactone), which is a low melting point thermoplastic biomaterial, for celladhesion studies (Figure 3e-f) . 33 There are many examples of research labs building or implement ing lowcost 3D printing platforms for biomaterials research and tissueengineering applications. 11, [33] [34] [35] [36] As outlined in the articles in this MRS Bulletin issue, materials researchers are now leveraging the accessibility of these machines to focus on innovations in bioinks, support materials, and applications.
Multiscale integration and post-processing
Although human organs comprise dozens of cell types and multiple matrix types, the majority of bioprinting research cur rently utilizes only a single extruder nozzle and two to three cell types in the final engineered construct. It remains unclear as to what extent these engineered systems, when cultured, correctly reproduce the exquisite complexity found in the human body with the underlying assumption that better replication of architectures found in the body will lead to better physiologic function (Figure 4) . 15, 34, 37 Thus, researchers are develop ing new generations of 3D printing capable of multihead or multimaterial fabrication. 14 Kang et al. developed an integrated four head extrusion system capable of dispensing poly(caprolactone) threads, cellular inks, and sacrificial inks to make an integrated tissueorgan printer, which was utilized in studies of cartilage, mandibular bone, and skeletal muscle. 38 Lind et al. demonstrated cardiac tissueonachip integrated systems in which cardiac tissue was deposited alongside electrical sensors that could sense and measure the contractile perfor mance of the tissue. 39 Additional materials investigations have centered on postprocessing to produce more complex scaffolds that cannot be produced by 3D printing. Jakus et al. demonstrated extrusion of hydroxyapatite mixed with poly(lacticco glycolic acid) and poly(caprolactone), and the resulting structures could be folded via origami to form new shapes that are not printable. 40 The scaffolds were also able to promote bone growth in vitro, as well as in vivo in a rhesus macaque.
Further pushing materials boundaries, researchers are introducing "fourdimensional printing" (4D), in which the printed structure can selfassemble into a predetermined state based on changing environmental factors. Gladman et al. printed flat shapes that could selfassemble into flowerlike morphologies through 3D printing of materials combinations, which could lead to anisotropic swelling. 41 However, the types of tissue architectures that could be addressed by 4D printing have yet to be demonstrated.
The future
The integration of printed materials and cells, and the design of the proper architectures in which to place them are antici pated to be the primary focus over the next decade of bioprint ing research. Scientists are determining the minimum feature set that is required in order to reconstitute organlevel function in controlled in vitro systems. Multidisciplinary teams will need to be formed composed not just of scientists, but also practicing clinicians who can advise on the final challenge of connecting engineered tissues directly to arteries and veins in a human patient. These exciting, burgenoning technologies and research communities promise to change the landscape of the medical industry and the ability to customize medical solutions for each individual patient. Multiscale considerations for bioprinting. Organ-level functions (depicted here as the entire liver) can be studied at the meso-and microscales. The mesoscale comprises the "vascular unit cell," which is a small functional unit of vascularized tissue with a patent vessel and supporting stromal and parenchymal organ-type cells that make up the rest of the organ-specific cells in the tissue. The microscale involves studying the phenotype of cells in the context of their immediate pericellular microenvironment where they receive and transmit chemical and biophysical cues and thereby provide function to the whole organism. These multiscale considerations can be studied through elaboration of principal architectural features, matrix and cellular components, and specific physiologic responses desired for study.
